Stem Cell Therapeutics Markets

Attention: There is an updated edition available for this report.
 
   Single User - $995
   Corporate License - $5,000


Loading...
Published Feb 1, 2009 | 150 Pages | Pub ID: KLI2021959

Political and business events presage change for stem cell therapeutics, most notably the expected move by President Barack Obama to lift federal funding restrictions on stem-cell research. The U.S. Congress has also indicated a desire to move forward with stem cell research. The momentum in two branches of American government, along with scientific developments and the competition of world markets presages good market conditions for stem cell research.

With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.

While companies have found opportunity outside the U.S., President Bush's seven year limitations on embryonic stem cell research in the U.S. has limited the U.S. market. Changes in U.S. policy should open up U.S. markets. For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells Therapeutics Markets. Kalorama analyst Alison Sahoo has built models to determine the best case and most likely case scenarios for therapeutic markets for stem cells in the coming years. This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:

  • Cardiovascular disease
  • Lung disease
  • Arthritis
  • Incontinence
  • Osteoporosis
  • Diabetes
  • Cancer
  • Orthopedics
  • Infertility
  • Alzheimer’s disease
  • Burns (severe)
  • Lupus
  • Parkinson’s disease
  • Liver failure
  • Multiple sclerosis
  • Critical limb ischemia
  • Crohn's disease
  • Sickle cell disease
  • Multiple myeloma
  • NH lymphoma
  • Leukemia
Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:
  • Aastrom Biosciences
  • Advanced Cell Technologies
  • Brainstorm Cell Therapeutics
  • Celegene
  • ES Cell International
  • Medistem
  • Neostem
  • Opexa Therapeutics
  • Osiris Therapeutics
  • Plureon
  • Regenetech
  • Revivicor
  • Stem Cell Sciences
  • StemLifeLine
  • ThermoGenesis
  • VetCell Bioscience
TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Recent Developments
  • Introduction
  • Current Stem Cell Therapies
  • Developmental Stem Cell Therapies
  • Issues in Stem Cell Research
  • Stem Cell Forecasts
  • Market Forecast
  • The Promise of Stem Cells in Medical Treatment
  • Types of Stem Cells
  • Embryonic Stem Cells
  • Important Developments in ES Cell Research
  • Adult Stem Cells
  • Important Developments
  • Scope and Methodology
CHAPTER TWO: CURRENT STEM CELL THERAPIES
  • Cancer
  • Leukemia
  • Gene Therapy
  • Multiple Myeloma
  • Non-Hodgkin’s Lymphoma Noncancerous Diseases
    • Aplastic Anemia
    • Immunodeficiency
    • Lupus
    • Sickle Cell Disease
    • Other Conditions
CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES
  • Alzheimer’s Disease
  • Arthritis
  • Burns
  • Cancer
  • Cardiovascular Conditions
  • Critical Limb Ischemia
  • Crohn’s Disease
  • Diabetes
  • Incontinence
  • Infertility
  • Liver Failure
  • Lung Disease
  • Multiple Sclerosis
  • Orthopedics
  • Osteoporosis
  • Parkinson’s Disease
  • Sickle Cell Disease
CHAPTER FOUR: STEM CELL MARKET FORECASTS
  • Best Case
    • Forecasts By Disease Area
    • Alzheimer’s Disease
    • Arthritis
    • Burns
    • Cancer,
    • Cardiovascular Conditions
    • Critical Limb Ischemia
    • Crohn’s Disease
    • Diabetes,
    • Incontinence
    • Infertility,
    • Liver Failure
    • Lung Disease
    • Multiple Sclerosis
    • Orthopedics
    • Osteoporosis
    • Parkinson’s Disease
    • Sickle Cell Disease
  • Most Likely Case
    • Forecasts By Disease Area
    • Alzheimer’s Disease
    • Arthritis
    • Burns
    • Cancer,
    • Cardiovascular Conditions
    • Critical Limb Ischemia
    • Crohn’s Disease
    • Diabetes,
    • Incontinence
    • Infertility,
    • Liver Failure
    • Lung Disease
    • Multiple Sclerosis
    • Orthopedics
    • Osteoporosis
    • Parkinson’s Disease
    • Sickle Cell Disease
CHAPTER FIVE: COMPANY PROFILES
  • Aastrom Biosciences
  • Advanced Cell Technologies
  • Athersys
  • Brainstorm Cell Therapeutics
  • Celegene
  • ES Cell International
  • Medistem
  • MultiCell Technologies, Inc.
  • Neostem
  • Nephros Therapeutics, Inc.
  • Opexa Therapeutics
  • Osiris Therapeutics
  • Plureon
  • Regenetech
  • Revivicor
  • Stem Cell Sciences
  • ThermoGenesis
  • VetCell Bioscience
LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-2: Stem Cell Therapeutics Market in $ Millions, 2007-2020

CHAPTER TWO: CURRENT STEM CELL THERAPIES

  • Table 2-1: Types of Leukemia, 2007

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES

  • Table 3-1: Global Disease Populations Addressed by Potential Stem Cell Therapies, 2007

  • Table 3-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020

  • Table 3-3: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2007 and 2020

  • Table 3-4: Types and Features of Urinary Incontinence, 2007

  • Table 3-5: Types and Causes of Male Infertility, 2007

  • Table 3-6: Common Diseases of the Lungs, 2007

CHAPTER FOUR: STEM CELL MARKET FORECASTS

  • Table 4-1: Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2007

  • Table 4-2: Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)

  • Table 4-3: Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)

  • Table 4-4: Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)

  • Table 4-5: Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)

CHAPTER FIVE: COMPANY PROFILES

  • Table 5-1: Therapeutic Focus of Selected Stem Cell Therapeutics Companies, 2007